1. Velden, N.M.A.B.a.W.J.F.M.v.d., Infections in the Immunocompromised Host: General Principles. 9 ed. Principles and Practice of Infectious Diseases. Vol. 2. 2019: Elsevier. 4895.
2. Li, Y., et al., Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi. Nat Med, 2016. 22(8): p. 952-60.
3. Quintana-Murci, L., et al., Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat Immunol, 2007. 8(11): p. 1165-71.
4. Bochud, P.Y., et al., Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis, 2007. 7(8): p. 531-42.
5. Dropulic, L.K. and H.M. Lederman, Overview of Infections in the Immunocompromised Host. Microbiol Spectr, 2016. 4(4).
6. Kumagai, Y. and S. Akira, Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol, 2010. 125(5): p. 985-92.
7. Takizawa, H., S. Boettcher, and M.G. Manz, Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood, 2012. 119(13): p. 2991-3002.
8. Wu, M.Y. and J.H. Lu, Autophagy and Macrophage Functions: Inflammatory Response and Phagocytosis. Cells, 2019. 9(1).
9. Martin-Fontecha, A., et al., Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol, 2004. 5(12): p. 1260-5.
10. Min-Oo, G., et al., Natural killer cells: walking three paths down memory lane. Trends Immunol, 2013. 34(6): p. 251-8.
11. Chi, H., M. Pepper, and P.G. Thomas, Principles and therapeutic applications of adaptive immunity. Cell, 2024. 187(9): p. 2052-2078.
12. Mackall, C.L., et al., Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood, 1994. 84(7): p. 2221-8.
13. Mackall, C.L., T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells, 2000. 18(1): p. 10-8.
14. Winthrop, K.L., et al., Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol, 2014. 66(10): p. 2675-84.
15. Kin, A. and C.A. Schiffer, Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies. Infect Dis Clin North Am, 2020. 34(2): p. 245-256.
16. Reinwald, M., et al., ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective
(Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect, 2018. 24 Suppl 2: p. S53-S70.
17. Lescuyer, S., et al., Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. Int J Infect Dis, 2019. 80: p.
134-136.
18. Telli Dizman, G., J.M. Aguado, and M. Fernandez-Ruiz, Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. Expert Rev
Anti Infect Ther, 2022. 20(11): p. 1455-1476.
19. Di Sabatino, A., R. Carsetti, and G.R. Corazza, Post-splenectomy and hyposplenic states. Lancet, 2011. 378(9785): p. 86-97.
20. Bodey, G.P., The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years. J Antimicrob Chemother, 2009. 63 Suppl 1: p. i3-13.
21. Rakoff-Nahoum, S., et al., Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 2004. 118(2): p. 229-41.
22. Taur, Y., et al., Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis, 2012. 55(7): p. 905-14.
23. Jenq, R.R., et al., Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med, 2012. 209(5): p. 903-11.
24. Sonis, S.T., et al., Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 2004. 100(9 Suppl): p. 1995-2025.
25. Vaes, M., et al., Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother, 2012. 56(12): p. 6298-303.
26. Evens, A.M., J. Mehta, and L.I. Gordon, Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant, 2004. 34(7): p. 561-71.
27. Ayaz, C.M., et al., Factors Associated with Gram-Negative Bacteremia and Mortality in Neutropenic Patients with Hematologic Malignancies in a High-Resistance Setting. Infect Dis Clin Micro-
biol, 2022. 4(2): p. 87-98.
28. Safdar, A., et al., Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis, 2006. 25(8): p. 522-6.
29. Germanakis, I., et al., Qualitative versus quantitative blood cultures in the diagnosis of catheter-related bloodstream infections in children with malignancy. Pediatr Blood Cancer, 2005. 45(7): p.
939-44.
30. Rupp, M.E. and R. Karnatak, Intravascular Catheter-Related Bloodstream Infections. Infect Dis Clin North Am, 2018. 32(4): p. 765-787.
31. Mikulska, M., et al., Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect, 2018. 76(1): p. 20-37.
32. Daly, C.G., et al., Bacteremia due to periodontal probing: a clinical and microbiological investigation. J Periodontol, 2001. 72(2): p. 210-4.
33. Maschmeyer, G. and J.P. Donnelly, How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation. Br J Haematol,
2016. 173(2): p. 179-89.
34. Seo, S., et al., Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies. Blood, 2015. 125(24): p. 3789-97.
35. Robert-Gangneux, F., et al., Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study. J Clin Microbiol, 2015. 53(5): p. 1677-84.
36. Santos, C.A., et al., Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients. Transplantation, 2015. 99(8):
p. 1658-66.
37. Woodward, J.M., et al., The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am J Gastroenterol, 2015. 110(2): p. 320-7.
38. Coleman, N., et al., Neutropenic enterocolitis associated with Clostridium tertium. J Clin Pathol, 1993. 46(2): p. 180-3.
39. Aksenova, M., et al., BK virus nephropathy in a pediatric patient after hematopoietic stem cell transplantation. Pediatr Transplant, 2015. 19(1): p. E29-32.
40. Ogata, M., T. Fukuda, and T. Teshima, Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant, 2015. 50(8):
p. 1030-6.
41. Versluis, J., et al., Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood, 2013. 122(6): p. 1079-86.
42. Chen, G., et al., A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients. Eur J Gast-
roenterol Hepatol, 2015. 27(8): p. 901